Artal Group Sa Stake in Fate Therapeutics INC (FATE) Trimmed by $5.95 Million

Investors sentiment decreased to 1.08 in 2019 Q1. Its down 0.52, from 1.6 in 2018Q4. It dived, as 11 investors sold FATE shares while 39 reduced holdings. 20 funds opened positions while 34 raised stakes. 55.48 million shares or 3.48% more from 53.61 million shares in 2018Q4 were reported. Arrowstreet Capital Limited Partnership owns 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE) for 19,300 shares. Rafferty Asset Mgmt Llc stated it has 106,400 shares. Proshare Advisors Limited Co has invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Vident Invest Advisory Limited Liability stated it has 96,315 shares or 0.09% of all its holdings. Partner Fund LP has invested 0.5% in Fate Therapeutics, Inc. (NASDAQ:FATE). Eam Invsts Limited Liability Com accumulated 0.31% or 70,799 shares. Fmr Ltd Com holds 0.01% in Fate Therapeutics, Inc. (NASDAQ:FATE) or 7.05M shares. The Switzerland-based Credit Suisse Ag has invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Amundi Pioneer Asset Mngmt owns 42,943 shares. 8,673 were reported by Tiverton Asset Management Ltd Llc. Westfield Management LP reported 893,425 shares. State Of Wisconsin Invest Board reported 0% stake. Alpinvest Partners Bv owns 21,104 shares for 0.5% of their portfolio. State Farm Mutual Automobile Insurance stated it has 28,144 shares or 0% of all its holdings. Tci Wealth Advsrs has invested 0.01% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE).

Artal Group Sa decreased its stake in Fate Therapeutics Inc (FATE) by 16.28% based on its latest 2019Q1 regulatory filing with the SEC. Artal Group Sa sold 350,000 shares as the company’s stock rose 35.11% . The institutional investor held 1.80M shares of the health care company at the end of 2019Q1, valued at $31.63 million, down from 2.15M at the end of the previous reported quarter. Artal Group Sa who had been investing in Fate Therapeutics Inc for a number of months, seems to be less bullish one the $1.15 billion market cap company. The stock decreased 1.62% or $0.29 during the last trading session, reaching $17.59. About 443,930 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 152.00% since August 15, 2018 and is uptrending. It has outperformed by 152.00% the S&P500.

Artal Group Sa, which manages about $2.45B US Long portfolio, upped its stake in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 150,000 shares to 1.15M shares, valued at $45.71 million in 2019Q1, according to the filing. It also increased its holding in Alder Biopharmaceuticals Inc (NASDAQ:ALDR) by 300,000 shares in the quarter, for a total of 500,000 shares, and has risen its stake in Tg Therapeutics Inc (NASDAQ:TGTX).

More notable recent Fate Therapeutics, Inc. (NASDAQ:FATE) news were published by: Nasdaq.com which released: “Jury weighs fate of Illinois man in gruesome slaying of student from China – Nasdaq” on July 17, 2019, also Finance.Yahoo.com with their article: “Fate Therapeutics, Inc. to Host Earnings Call – Yahoo Finance” published on August 06, 2019, Seekingalpha.com published: “Fate Therapeutics Q2 2019 Earnings Preview – Seeking Alpha” on August 05, 2019. More interesting news about Fate Therapeutics, Inc. (NASDAQ:FATE) were released by: Seekingalpha.com and their article: “Sell-siders bullish on BridgeBio in premarket analyst action – Seeking Alpha” published on July 22, 2019 as well as Nasdaq.com‘s news article titled: “Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? – Nasdaq” with publication date: February 25, 2019.

Fate Therapeutics, Inc. (NASDAQ:FATE) Ratings Coverage

Among 4 analysts covering Fate Therapeutics (NASDAQ:FATE), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Fate Therapeutics has $2700 highest and $12 lowest target. $20.60’s average target is 17.11% above currents $17.59 stock price. Fate Therapeutics had 12 analyst reports since March 6, 2019 according to SRatingsIntel. The firm has “Hold” rating by H.C. Wainwright given on Wednesday, March 6. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) earned “Buy” rating by Wells Fargo on Wednesday, March 6.

Fate Therapeutics, Inc. (NASDAQ:FATE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.